Literature DB >> 3940402

Adrenal tissue characterization using MR imaging.

G M Glazer, E J Woolsey, J Borrello, I R Francis, A M Aisen, F Bookstein, M A Amendola, M D Gross, R L Bree, W Martel.   

Abstract

Using a superconducting magnet operating at 0.35 T, the authors investigated the adrenal tissue characterization potential of magnetic resonance (MR) in 28 patients with 33 adrenal masses. There were 13 adrenal adenomas (12 non-hyperfunctioning, one aldosteronoma), nine adrenal metastases, four pheochromocytomas, two neuroblastomas, two adrenal lymphomas, two myelolipomas, and one adrenal cortical carcinoma. Spin-echo pulse sequences were obtained at TR 0.5, 2.0 sec and TE 28, 56 msec. Both qualitative (visual assessment) and quantitative (absolute signal intensity, intensity ratios, T1, T2) data were used for tissue characterization. The results suggest that non-hyperfunctioning adrenal adenomas can be distinguished from non-adenomas using both qualitative and quantitative data: 16/19 non-adenomas were visually hyperintense compared with liver at TR 2.0 sec, TE 56 msec, while none of the non-hyperfunctioning adenomas was relatively hyperintense at any pulse sequence used. Of the quantitative data, the intensity ratios of adrenal lesion/liver at TR 0.5 sec, TE 56 msec were most useful in diagnosis: all adenomas had ratios less than 0.83, while 19/20 non-adenomas had ratios exceeding this value. It is concluded that MR has considerable promise in adrenal tissue characterization.

Entities:  

Mesh:

Year:  1986        PMID: 3940402     DOI: 10.1148/radiology.158.1.3940402

Source DB:  PubMed          Journal:  Radiology        ISSN: 0033-8419            Impact factor:   11.105


  14 in total

Review 1.  Percutaneous renal and adrenal biopsies.

Authors:  V G Vassiliades; M E Bernardino
Journal:  Cardiovasc Intervent Radiol       Date:  1991 Jan-Feb       Impact factor: 2.740

Review 2.  Evaluation of primary adrenal insufficiency secondary to tuberculous adrenalitis with computed tomography and magnetic resonance imaging: Current status.

Authors:  Yu-Cheng Huang; Yu-Lian Tang; Xiao-Ming Zhang; Nan-Lin Zeng; Rui Li; Tian-Wu Chen
Journal:  World J Radiol       Date:  2015-10-28

3.  Scintigraphy of incidentally discovered bilateral adrenal masses.

Authors:  M D Gross; B Shapiro; I R Francis; R L Bree; M Korobkin; M K McLeod; N W Thompson; J A Sanfield
Journal:  Eur J Nucl Med       Date:  1995-04

4.  Screening for adrenal medullary disease in patients with medullary thyroid carcinoma.

Authors:  F Bonnin; M Schlumberger; P Gardet; F Tenenbaum; J Lumbroso; J Leclere; E Comoy; A Megnigbeto; J P Travagli; C Parmentier
Journal:  J Endocrinol Invest       Date:  1994-04       Impact factor: 4.256

5.  Adrenal macrotumors diagnosed by computed tomography.

Authors:  J M López; C Fardella; E Arteaga; P Michaud; J A Rodriguez; F Cruz
Journal:  J Endocrinol Invest       Date:  1990 Jul-Aug       Impact factor: 4.256

Review 6.  Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities.

Authors:  A P van Gils; A R van Erkel; T H Falke; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1994-03

Review 7.  The indeterminate adrenal lesion.

Authors:  Anju Sahdev; Jon Willatt; Isaac R Francis; Rodney H Reznek
Journal:  Cancer Imaging       Date:  2010-03-18       Impact factor: 3.909

8.  The role of adrenocortical scintigraphy in the evaluation of unilateral incidentally discovered adrenal and juxtaadrenal masses.

Authors:  M Nakajo; Y Nakabeppu; R Yonekura; S Iwashita; T Goto
Journal:  Ann Nucl Med       Date:  1993-08       Impact factor: 2.668

9.  Leiomyoma of the adrenal gland in a patient with AIDS.

Authors:  H Dahan; C Bèges; L Weiss; M Abitbol; O Ledreff; G Teman; K Belattar; R Rymer
Journal:  Abdom Imaging       Date:  1994 May-Jun

Review 10.  The indeterminate adrenal mass in patients with cancer.

Authors:  A Sahdev; R H Reznek
Journal:  Cancer Imaging       Date:  2007-10-01       Impact factor: 3.909

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.